Brokerages Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Price Target at $14.28

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have been given a consensus rating of “Moderate Buy” by the five research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.2750.

Several research firms have recently commented on NAGE. Wall Street Zen cut Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, HC Wainwright lifted their target price on shares of Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, August 11th.

Niagen Bioscience Stock Down 1.0%

NASDAQ NAGE opened at $6.86 on Friday. The firm has a market cap of $547.47 million, a P/E ratio of 32.67 and a beta of 2.17. Niagen Bioscience has a 52-week low of $5.16 and a 52-week high of $14.69. The business’s 50-day moving average price is $8.00 and its 200 day moving average price is $9.82.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.The firm had revenue of $33.99 million during the quarter, compared to the consensus estimate of $31.30 million.

Insiders Place Their Bets

In other Niagen Bioscience news, CFO Ozan Pamir acquired 4,465 shares of the stock in a transaction on Friday, November 14th. The shares were bought at an average price of $6.81 per share, with a total value of $30,406.65. Following the acquisition, the chief financial officer owned 7,372 shares of the company’s stock, valued at $50,203.32. This trade represents a 153.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.39% of the company’s stock.

Institutional Trading of Niagen Bioscience

Hedge funds have recently modified their holdings of the business. Silverberg Bernstein Capital Management LLC acquired a new position in Niagen Bioscience during the third quarter worth $1,169,000. BSW Wealth Partners purchased a new stake in shares of Niagen Bioscience during the 3rd quarter worth $793,000. CWM LLC purchased a new stake in shares of Niagen Bioscience during the 3rd quarter worth $246,000. Precision Wealth Strategies LLC acquired a new position in shares of Niagen Bioscience during the 3rd quarter worth $1,527,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Niagen Bioscience in the 3rd quarter valued at about $144,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.